ALLR

Allarity is a pre-revenue, clinical-stage oncology shell whose entire value now rests on one in-licensed Phase 2 asset — stenoparib for recurrent ovarian cancer — after it terminated dovitinib, Irofulven and LiPlaCis and Novartis handed back an asset in January 2024. The $320K of FY2025 'revenue' is a rounding error against a -$12.6M operating loss (operating margin -3,939%) and a -$130M accumulated deficit; the P/S of 64.8x is meaningless because there is no real commercial business to value. This is a cash-runway-and-catalyst story, not a fundamentals story, and the runway is thin: $14.7M cash (down 24.8% YoY) against -$14.8M operating cash flow implies roughly one year before another dilutive raise. Shares outstanding are already tiny at 15.8M after an authorized-share reduction, and history shows brutal dilution/reverse-split math (FY2023 diluted EPS of -$10.26).

The filing language deepens the risk rather than relieving it. Management concedes it 'may be unable to meet the payment requirements' of the sixth amended Eisai license and 'may lose our right to use stenoparib' — meaning the company's sole remaining asset can be pulled if it can't fund milestone obligations (up to $94M in total milestones plus tiered royalties). Eisai also retains an option to reacquire the licensed rights. So the one thing that gives ALLR any equity value is contractually contingent on continuous financing that management explicitly flags as uncertain. The balance sheet looks superficially okay (liabilities/equity 0.86x, current assets $17.9M vs $8.43M current liabilities), but nearly all of that equity is cash that is actively being consumed.